8-K: Cigna Group Reports Strong 2024 Revenue Growth, Increases Dividend and Share Repurchase Program

The Cigna Group announced a 27% increase in 2024 revenue, a dividend increase, and a significant boost to its share repurchase program, despite challenges in its healthcare segment.

Summary

• The Cigna Group reported a 27% increase in total revenues for 2024, reaching $247.1 billion.
• Shareholders' net income for 2024 was $3.4 billion, or $12.12 per share, which includes a $2.7 billion non-cash after-tax investment loss related to VillageMD.
• Adjusted income from operations for 2024 was $7.7 billion, or $27.33 per share.
• The company projects its 2025 adjusted income from operations to be at least $7.9 billion, or at least $29.50 per share.
• The Board of Directors approved an 8% increase in the quarterly dividend to $1.51 per share.
• An additional $6.0 billion was authorized for share repurchases, bringing the total authorization to $10.3 billion.
• Fourth quarter 2024 revenue increased by 28% compared to the same period in 2023, driven by growth in Evernorth Health Services.
• Adjusted income from operations for the fourth quarter of 2024 decreased by 8% compared to the fourth quarter of 2023, primarily due to higher stop-loss medical costs in Cigna Healthcare.
• Total customer relationships increased by 11% to 182.2 million by the end of 2024.
• Pharmacy customers increased by 20% to 118.3 million, while medical customers decreased slightly to 19.1 million.

Sentiment

Score: 6

Explanation: The document presents mixed results with strong revenue growth offset by lower net income and higher medical costs. The increased dividend and share repurchase program are positive, but the challenges in the healthcare segment temper the overall sentiment.

Positives

• Total revenues for 2024 saw a significant increase of 27%, reaching $247.1 billion.
• Evernorth Health Services demonstrated strong growth with a 32% increase in adjusted revenues for the full year.
• The company increased its quarterly dividend by 8% to $1.51 per share.
• The share repurchase program was significantly boosted with an additional $6.0 billion authorization.
• The SG&A expense ratio improved to 6.0% for 2024, indicating increased efficiency.
• Total customer relationships increased by 11% to 182.2 million.

Negatives

• Shareholders' net income for 2024 decreased to $3.4 billion, compared to $5.2 billion in 2023, due to a $2.7 billion non-cash after-tax investment loss related to VillageMD.
• Cigna Healthcare experienced a decrease in adjusted income from operations, primarily due to higher stop-loss medical costs.
• The medical care ratio (MCR) for Cigna Healthcare increased to 83.2% for the full year 2024, indicating higher medical costs.
• Adjusted income from operations for the fourth quarter of 2024 decreased by 8% compared to the fourth quarter of 2023.

Risks

• Higher stop-loss medical costs in Cigna Healthcare are impacting earnings and require corrective actions.
• The company faces challenges in managing medical costs, as indicated by the increased medical care ratio.
• The non-cash after-tax investment loss of $2.7 billion related to VillageMD significantly impacted net income.
• The company's future performance is subject to various factors, including economic conditions and regulatory changes.

Future Outlook

The Cigna Group projects its 2025 adjusted income from operations to be at least $7.9 billion, or at least $29.50 per share, and anticipates the divestiture of its Medicare businesses to close in the first quarter of 2025. The company also expects cash flow from operations of approximately $10 billion, capital expenditures of approximately $1.4 billion, and shareholder dividends of approximately $1.6 billion.

Management Comments

• David M. Cordani, chairman and CEO of The Cigna Group, stated that while higher medical costs in the stop loss product impacted fourth quarter earnings, the company is taking corrective actions and advancing its long-term growth strategy.
• Management is focused on building a sustainable healthcare model by addressing transparency, support, and value for patients and clients.

Industry Context

The Cigna Group's results reflect the broader trends in the healthcare industry, including the increasing focus on pharmacy benefit services and the challenges of managing medical costs. The company's growth in Evernorth Health Services aligns with the industry's shift towards integrated healthcare solutions. The higher medical costs in Cigna Healthcare highlight the ongoing pressures on health insurers to control expenses.

Comparison to Industry Standards

• Cigna's 27% revenue growth in 2024 is strong compared to peers like UnitedHealth Group and Anthem, which have also seen revenue growth but not at the same rate.
• The increase in Cigna's medical care ratio (MCR) to 83.2% is a concern, as it indicates higher medical costs relative to premiums. This is higher than some competitors, such as Humana, which have been focusing on cost containment.
• Cigna's share repurchase program increase to $10.3 billion is a significant move, demonstrating confidence in the company's future performance and is larger than many of its peers.
• The projected 2025 adjusted income from operations of at least $7.9 billion is a positive outlook, but the company needs to address the higher medical costs in its healthcare segment to meet these targets.
• The divestiture of the Medicare business is a strategic move that aligns with other large health insurers who are focusing on specific segments of the market.

Stakeholder Impact

• Shareholders will benefit from the increased dividend and share repurchase program.
• Customers may see changes in healthcare plans and services as the company addresses medical cost issues.
• Employees may be affected by the company's strategic and operational initiatives.
• Suppliers and partners may experience changes in business relationships as the company adjusts its operations.

Next Steps

• The company will continue to take corrective actions to address higher stop-loss medical costs in Cigna Healthcare.
• The company will focus on advancing its long-term growth strategy.
• The divestiture of the company's Medicare businesses is expected to close in the first quarter of 2025.
• Management will host a conference call to review fourth quarter and full year 2024 results and discuss the full year 2025 outlook.

Key Dates

Keywords

Cigna Group, Healthcare, Evernorth Health Services, Financial Results, Dividend, Share Repurchase, Medical Costs, Pharmacy Benefit Services, Adjusted Income, Revenue